0.368
0.00 (0.82%)
| Previous Close | 0.365 |
| Open | 0.360 |
| Volume | 46,981 |
| Avg. Volume (3M) | 195,450 |
| Market Cap | 12,351,360 |
| Price / Sales | 2.67 |
| Price / Book | 0.210 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Operating Margin (TTM) | -7,973.90% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -95.80% |
| Total Debt/Equity (MRQ) | 3.96% |
| Current Ratio (MRQ) | 4.41 |
| Operating Cash Flow (TTM) | -29.16 M |
| Levered Free Cash Flow (TTM) | -16.45 M |
| Return on Assets (TTM) | -31.45% |
| Return on Equity (TTM) | -53.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Co-Diagnostics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 2.13 |
|
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 7.83% |
| % Held by Institutions | 17.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Private Advisory Group Llc | 31 Dec 2024 | 1,181,633 |
| Koss-Olinger Consulting, Llc | 31 Dec 2024 | 58,102 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (D. Boral Capital, 2,618.13%) | Buy |
| Median | 5.50 (1,394.97%) | |
| Low | 1.00 (HC Wainwright & Co., 171.81%) | Hold |
| Average | 5.50 (1,394.97%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 0.346 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 28 Apr 2025 | 10.00 (2,618.13%) | Buy | 0.371 |
| HC Wainwright & Co. | 28 Mar 2025 | 1.00 (171.81%) | Hold | 0.320 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2025 | Announcement | Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference |
| 08 May 2025 | Announcement | Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results |
| 29 Apr 2025 | Announcement | Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast |
| 27 Mar 2025 | Announcement | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results |
| 13 Mar 2025 | Announcement | Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast |
| 06 Mar 2025 | Announcement | Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit |
| 03 Mar 2025 | Announcement | Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025 |
| 21 Feb 2025 | Announcement | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |